Novo Nordisk Reveals Tresiba US Pricing Premium To Levemir
This article was originally published in Scrip
Novo Nordisk AS says its ultra-long-acting insulin Tresiba will be launched in the US at a 10% premium to the Danish company's currently marketed Levemir (insulin detemir) and made available first to specialists and pharmacies there in the fourth quarter, with full commercial launch slated for the first quarter of 2016.
You may also be interested in...
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.
Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.
Novo Nordisk’s 6 August Q2 update will be scrutinized for clues on its plans for semaglutide in obesity, sales data for diabetes drugs Rybelsus and Ozempic, and likely M&A.